This article is more than 5 years old. Information may no longer be current.

PROTECT study shows combined anti-VEGF, PDT therapy safe at 9 months

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

VIENNA — Verteporfin photodynamic therapy combined with ranibizumab 0.5 mg, both administered on the same day, shows safe results at 9 months follow-up, according to an award-winning poster study presented here at the European Society of Ophthalmology meeting.

Sebastian Wolf, MD, PhD, and colleagues conducting the PROTECT study said that the same-day treatment resulted in a reduction of central retinal thickness up to 9 months. It also led to a decrease in overall mean greatest lesion dimension and leakage stabilization up to 9 months, according to the study.

The PROTECT study is an open-label, multicenter, phase 2 study investigating the efficacy of same-day verteporfin (Visudyne, Novartis/QLT) and ranibizumab (Lucentis, Genentech) against exudative age-related macular degeneration. Outcomes are assessed using fluorescein angiography, fundus photography and optical coherence tomography.